Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
QoL · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in loss of ≥ 15 letters BCVA at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
QoL · adults with GA due to AMD
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD
1 finding from 1 review
Change in untransformed GA lesion size from baseline at 1 year (mm²) · adults with GA due to AMD
1 finding from 1 review
Comfort · Adults with refractive errors
The review found no eligible studies for this question.
3 findings from 1 review
Proportion of participants who discontinued contact lens wear, at 1 week (RR < 1 favored) · Adults with refractive errors
It is very uncertain whether silicone hydrogel changes proportion of participants who discontinued contact lens wear, at 1… compared with hydrogel soft contact lenses (very low certainty).
1 finding from 1 review
Corneal staining scores, at 1 week (MD < 0 favored) · Adults with refractive errors
It is very uncertain whether silicone hydrogel changes corneal staining scores, at 1 week (MD < 0 favored) compared with hydrogel soft contact lenses (very low certainty).
1 finding from 1 review
Conjunctival staining scores, at 1 month (MD < 0 favored) · Adults with refractive errors
It is very uncertain whether silicone hydrogel changes conjunctival staining scores, at 1 month (MD < 0 favored) compared with hydrogel soft contact lenses (very low certainty).
1 finding from 1 review
Proportion of participants with vision‐threatening adverse events (RR < 1 favored) · Adults with refractive errors
1 finding from 1 review
no estimate extracted
4 participants
Very low
Intervention not reported
All‐cause death · patients with neovascular age‐related macular degeneration
The intervention showed no clear difference in all‐cause death (moderate certainty).
1 finding from 1 review
Intervention not reported
All serious systemic adverse events · patients with neovascular age‐related macular degeneration
The intervention showed no clear difference in all serious systemic adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Infection · patients with neovascular age‐related macular degeneration
The intervention showed no clear difference in infection (moderate certainty).
1 finding from 1 review
Intervention not reported
Arterial thromboembolic event · patients with neovascular age‐related macular degeneration
The intervention showed no clear difference in arterial thromboembolic event (moderate certainty).
1 finding from 1 review
Intervention not reported
Myocardial infarction · patients with neovascular age‐related macular degeneration
The intervention showed no clear difference in myocardial infarction (moderate certainty).
1 finding from 1 review
Intervention not reported
Stroke · patients with neovascular age‐related macular degeneration
The intervention showed no clear difference in stroke (moderate certainty).
1 finding from 1 review
Intervention not reported
Gastrointestinal disorders MedDRA class · patients with neovascular age‐related macular degeneration
The intervention probably leads to higher gastrointestinal disorders MedDRA class (moderate certainty).
1 finding from 1 review